Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial

Ähnliche Einträge

• Pioglitazone after ischemic stroke or transient ischemic attack
  von: Kernan, Walter N., et al.
  Veröffentlicht: (2016)
• Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial
  von: Viscoli, Catherine M., et al.
  Veröffentlicht: (2014)
• Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial
  von: Amarenco, Pierre, et al.
  Veröffentlicht: (2010)
• Rationale and design of the prevention of cerebrovascular and cardiovascular events of ischemic origin with Terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
  von: Hennerici, Michael G.
  Veröffentlicht: (2009)
• One-year risk of stroke after transient ischemic attack or minor stroke
  von: Amarenco, Pierre, et al.
  Veröffentlicht: (2016)